SCHEMBL4895912

SCHEMBL4895912

O=C(NCc1ccccc1O)c1ccc(-c2cccc(Cl)c2)o1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.65
RAB9A P51151 3/20 0.65
S1PR4 O95977 1/20 0.55
SMN1; SMN2 Q16637 4/20 0.53
HPGD P15428 4/20 0.53
NPC1 O15118 2/20 0.53
MAPT P10636 5/20 0.51
KDM4E B2RXH2 4/20 0.51
LMNA P02545 3/20 0.51
GAA P10253 2/20 0.50
MGAM O43451 1/20 0.50
SI P14410 1/20 0.50
MGAM2 Q2M2H8 1/20 0.50
MEN1 O00255 1/20 0.49
PRKD3 O94806 1/20 0.49
KMT2A Q03164 1/20 0.49
PRKD1 Q15139 1/20 0.49
PRKD2 Q9BZL6 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
SLC9A1 P19634 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4894551 0.85 ALDH1A1 (0.68) ALDH1A1RAB9AS1PR4SMN1; SMN2HPGD
SCHEMBL4896863 0.84 ALDH1A1 (0.69) ALDH1A1RAB9AS1PR4SMN1; SMN2HPGD
SCHEMBL4896955 0.82 ALDH1A1 (0.67) ALDH1A1RAB9AS1PR4SMN1; SMN2HPGD
SCHEMBL4894773 0.82 KDM4E (0.57) ALDH1A1RAB9ASMN1; SMN2HPGDMAPT
SCHEMBL4897438 0.80 ALDH1A1 (0.64) ALDH1A1RAB9AS1PR4SMN1; SMN2HPGD
SCHEMBL29195048 0.79 ALDH1A1 (0.65) ALDH1A1RAB9AS1PR4SMN1; SMN2HPGD
SCHEMBL30715120 0.79 ALDH1A1 (0.65) ALDH1A1RAB9AS1PR4SMN1; SMN2HPGD
SCHEMBL20764223 0.77 ALDH1A1 (0.60) ALDH1A1RAB9AS1PR4SMN1; SMN2HPGD
SCHEMBL4896467 0.76 ALDH1A1 (0.62) ALDH1A1RAB9AS1PR4SMN1; SMN2HPGD
SCHEMBL29195059 0.74 S1PR4 (0.60) ALDH1A1RAB9AS1PR4SMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8815924-B2 Heterocyclic carbonyl compounds MERCK PATENT GMBH (DE) 2014-08-26 US claimed
US-20080090882-A1 Inhibitors of kinase h-sgk (human serum and glucocorticoid dependent kinase or SGK); diabetes, obesity, metabolic syndrome, systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, fibroses and inflammatory processes; amide-substituted imidazoles, oxazoles, thiazoles, or furans MERCK PATENT GMBH (DE) 2008-04-17 US claimed
US-8815924-B2 Heterocyclic carbonyl compounds MERCK PATENT GMBH (DE) 2014-08-26 US disclosed
US-20080090882-A1 Inhibitors of kinase h-sgk (human serum and glucocorticoid dependent kinase or SGK); diabetes, obesity, metabolic syndrome, systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, fibroses and inflammatory processes; amide-substituted imidazoles, oxazoles, thiazoles, or furans MERCK PATENT GMBH (DE) 2008-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090882-A1 Inhibitors of kinase h-sgk (human serum and glucocorticoid dependent kinase or SGK); diabetes, obesity, metabolic syndrome, systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, fibroses and inflammatory processes; amide-substituted imidazoles, oxazoles, thiazoles, or furans SGK1, SGK2, SGK3 ALDH1A1 3961/4885RAB9A 4509/4885S1PR4 2025/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.